Based on the protective effect of Trim31 in NAFLD, we accordingly investigated the therapeutic feasibility and effect of targeting the Trim31-Rhbdf2-MAP3K7 pathway in the development and progression of NASH. Here, RHBDF2 is linked to metabolic dysfunction-associated steatotic liver disease.